PMID- 27826987
OWN - NLM
STAT- MEDLINE
DCOM- 20170807
LR  - 20171116
IS  - 1941-837X (Electronic)
IS  - 1369-6998 (Linking)
VI  - 20
IP  - 3
DP  - 2017 Mar
TI  - Healthcare costs of urinary tract infections and genital mycotic infections among 
      patients with type 2 diabetes mellitus initiated on canagliflozin: a 
      retrospective cohort study.
PG  - 303-313
LID - 10.1080/13696998.2016.1259167 [doi]
AB  - OBJECTIVE: To assess the economic impact of urinary tract infections (UTIs) and 
      genital mycotic infections (GMIs) among patients with type 2 diabetes mellitus 
      (T2DM) initiated on canagliflozin. METHODS: Administrative claims data from April 
      2013 through June 2014 MarketScan((R)) databases were extracted. Adults with >/=1 
      claim for canagliflozin, T2DM diagnosis, and >/=90 days enrollment before and after 
      canagliflozin initiation were propensity score matched to controls with T2DM 
      initiated on other anti-hyperglycemic agents (AHAs). UTI and GMI healthcare costs 
      were evaluated 90-days post-index and reported as cohort means. RESULTS: Rates of 
      UTI claims 90 days post-index were similar in patients receiving canagliflozin 
      for T2DM (n = 31,257) and matched controls (2.7% vs 2.8%, p = .677). More 
      canagliflozin than control patients had GMI claims (1.2% vs 0.6%, p < .001) and 
      antifungal utilization (5.3% vs 2.6%, p < .001). Mean post-index costs to treat 
      UTIs were lower but not significantly different for canagliflozin patients vs 
      matched controls ($27.61 vs $37.33, p = .150). GMI treatment costs were higher 
      for the canagliflozin cohort ($3.68 vs $2.44, p = .041). Combined costs to treat 
      either UTI and/or GMI averaged $31.29 per patient for the canagliflozin cohort v 
      $39.77 for controls (p = .211). Rates and costs of UTIs and GMIs were higher for 
      females than males, but the canagliflozin vs control trends observed for the 
      overall sample were similar for both sexes. There were no significant cost 
      differences between the canagliflozin and control cohorts among patients aged 
      18-64. Among patients aged 65 and above, GMI treatment costs were not 
      significantly different, but costs to treat UTIs and either UTI and/or GMI were 
      significantly lower for canagliflozin patients vs controls. CONCLUSIONS: In a 
      real-world setting, the costs to payers of treating UTIs and GMIs are generally 
      similar for patients with T2DM initiated on canagliflozin vs other AHAs.
FAU - Amos, Tony B
AU  - Amos TB
AD  - a Janssen Scientific Affairs, LLC , USA.
FAU - Montejano, Leslie
AU  - Montejano L
AD  - b Truven Health Analytics, an IBM Company , USA.
FAU - Juneau, Paul
AU  - Juneau P
AD  - b Truven Health Analytics, an IBM Company , USA.
FAU - Bolge, Susan C
AU  - Bolge SC
AD  - a Janssen Scientific Affairs, LLC , USA.
LA  - eng
PT  - Journal Article
DEP - 20161128
PL  - England
TA  - J Med Econ
JT  - Journal of medical economics
JID - 9892255
RN  - 0 (Hypoglycemic Agents)
RN  - 0SAC974Z85 (Canagliflozin)
SB  - IM
MH  - Adolescent
MH  - Adult
MH  - *Canagliflozin
MH  - Contraindications
MH  - Databases, Factual
MH  - Diabetes Mellitus, Type 2/*drug therapy
MH  - Female
MH  - Health Care Costs
MH  - Humans
MH  - *Hypoglycemic Agents
MH  - Male
MH  - Middle Aged
MH  - Mycoses/*chemically induced/*economics
MH  - Retrospective Studies
MH  - Urinary Tract Infections/*chemically induced/*economics
MH  - Young Adult
OTO - NOTNLM
OT  - Type 2 diabetes mellitus
OT  - canagliflozin
OT  - cost of UTI/GMI events
OT  - genital mycotic infection (GMI)
OT  - urinary tract infection (UTI)
EDAT- 2016/11/09 06:00
MHDA- 2017/08/08 06:00
CRDT- 2016/11/10 06:00
PHST- 2016/11/09 06:00 [pubmed]
PHST- 2017/08/08 06:00 [medline]
PHST- 2016/11/10 06:00 [entrez]
AID - 10.1080/13696998.2016.1259167 [doi]
PST - ppublish
SO  - J Med Econ. 2017 Mar;20(3):303-313. doi: 10.1080/13696998.2016.1259167. Epub 2016 
      Nov 28.